Selective in vivo binding of [3H]naltriben to δ-opioid receptors in mouse brain

John R. Lever, Ursula Scheffel

Research output: Contribution to journalArticle

Abstract

Naltriben (NTB) is a selective antagonist for the putative δ2-opioid receptor. We have determined the regional kinetics and pharmacological profile of [3H]naltriben in vivo in mouse brain. After i.v. administration to CD1 mice, [3H]naltriben uptake and retention were high in striatum, cortical regions and olfactory tubercles, and low in superior colliculi and cerebellu. Robust rank order correlation was found between [3H]naltriben uptake in discrete brain regions and prior δ-opioid receptor binding determinations in vitro and in vivo [3H]Naltriben binding in vivo was saturable, and was blocked by the δ-opioid receptor antagonist naltrindole, but not by the μ-opioid receptor antagonist cyprodime or the κ-opioid receptor agonist (trans)-(±)-3,4-dicholoro-N-methyl-N-[2-(1-pyrrolidinyl)- cyclohexyl]benzeneacetamide mesylate (U50, 488H). (E)-7- Benzylidenenaltrexone (BNTX), a selective antagonist for the putative δ1- opioid receptor, was 9.6- to 12.9-fold less potent than naltriben as an inhibitor of [3H]naltriben binding. Thus, the sites labeled by [3H]naltriben in vivo may correspond to the δ2-opioid receptor subtype. Such assignment is not definitive, particularly considering the 4-fold higher brain uptake of naltriben as compared to (E)-7-benzylidenenaltrexone. Moreover, the regional distribution of [3H]naltriben in brains from CXB- 7/BY (CXBK) mice, a strain that shows supraspinal δ1- but not δ2-opioid receptor agonist effects, was quite similar to that found for CD1 mice.

Original languageEnglish (US)
Pages (from-to)335-344
Number of pages10
JournalEuropean Journal of Pharmacology
Volume350
Issue number2-3
DOIs
StatePublished - Jun 5 1998

Fingerprint

Opioid Receptors
Brain
naltrindole
Narcotic Antagonists
Benzeneacetamides
naltrindole benzofuran
Mesylates
Superior Colliculi
Pharmacology

Keywords

  • δ-Opioid receptor
  • Benzylidenenaltrexone
  • Binding
  • Brain
  • CD1 mouse
  • CXBK mouse
  • In vivo
  • Naltriben

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Pharmacology

Cite this

Selective in vivo binding of [3H]naltriben to δ-opioid receptors in mouse brain. / Lever, John R.; Scheffel, Ursula.

In: European Journal of Pharmacology, Vol. 350, No. 2-3, 05.06.1998, p. 335-344.

Research output: Contribution to journalArticle

@article{ab2469c9616a4ad3a472abb11d2bcb98,
title = "Selective in vivo binding of [3H]naltriben to δ-opioid receptors in mouse brain",
abstract = "Naltriben (NTB) is a selective antagonist for the putative δ2-opioid receptor. We have determined the regional kinetics and pharmacological profile of [3H]naltriben in vivo in mouse brain. After i.v. administration to CD1 mice, [3H]naltriben uptake and retention were high in striatum, cortical regions and olfactory tubercles, and low in superior colliculi and cerebellu. Robust rank order correlation was found between [3H]naltriben uptake in discrete brain regions and prior δ-opioid receptor binding determinations in vitro and in vivo [3H]Naltriben binding in vivo was saturable, and was blocked by the δ-opioid receptor antagonist naltrindole, but not by the μ-opioid receptor antagonist cyprodime or the κ-opioid receptor agonist (trans)-(±)-3,4-dicholoro-N-methyl-N-[2-(1-pyrrolidinyl)- cyclohexyl]benzeneacetamide mesylate (U50, 488H). (E)-7- Benzylidenenaltrexone (BNTX), a selective antagonist for the putative δ1- opioid receptor, was 9.6- to 12.9-fold less potent than naltriben as an inhibitor of [3H]naltriben binding. Thus, the sites labeled by [3H]naltriben in vivo may correspond to the δ2-opioid receptor subtype. Such assignment is not definitive, particularly considering the 4-fold higher brain uptake of naltriben as compared to (E)-7-benzylidenenaltrexone. Moreover, the regional distribution of [3H]naltriben in brains from CXB- 7/BY (CXBK) mice, a strain that shows supraspinal δ1- but not δ2-opioid receptor agonist effects, was quite similar to that found for CD1 mice.",
keywords = "δ-Opioid receptor, Benzylidenenaltrexone, Binding, Brain, CD1 mouse, CXBK mouse, In vivo, Naltriben",
author = "Lever, {John R.} and Ursula Scheffel",
year = "1998",
month = "6",
day = "5",
doi = "10.1016/S0014-2999(98)00268-4",
language = "English (US)",
volume = "350",
pages = "335--344",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "2-3",

}

TY - JOUR

T1 - Selective in vivo binding of [3H]naltriben to δ-opioid receptors in mouse brain

AU - Lever, John R.

AU - Scheffel, Ursula

PY - 1998/6/5

Y1 - 1998/6/5

N2 - Naltriben (NTB) is a selective antagonist for the putative δ2-opioid receptor. We have determined the regional kinetics and pharmacological profile of [3H]naltriben in vivo in mouse brain. After i.v. administration to CD1 mice, [3H]naltriben uptake and retention were high in striatum, cortical regions and olfactory tubercles, and low in superior colliculi and cerebellu. Robust rank order correlation was found between [3H]naltriben uptake in discrete brain regions and prior δ-opioid receptor binding determinations in vitro and in vivo [3H]Naltriben binding in vivo was saturable, and was blocked by the δ-opioid receptor antagonist naltrindole, but not by the μ-opioid receptor antagonist cyprodime or the κ-opioid receptor agonist (trans)-(±)-3,4-dicholoro-N-methyl-N-[2-(1-pyrrolidinyl)- cyclohexyl]benzeneacetamide mesylate (U50, 488H). (E)-7- Benzylidenenaltrexone (BNTX), a selective antagonist for the putative δ1- opioid receptor, was 9.6- to 12.9-fold less potent than naltriben as an inhibitor of [3H]naltriben binding. Thus, the sites labeled by [3H]naltriben in vivo may correspond to the δ2-opioid receptor subtype. Such assignment is not definitive, particularly considering the 4-fold higher brain uptake of naltriben as compared to (E)-7-benzylidenenaltrexone. Moreover, the regional distribution of [3H]naltriben in brains from CXB- 7/BY (CXBK) mice, a strain that shows supraspinal δ1- but not δ2-opioid receptor agonist effects, was quite similar to that found for CD1 mice.

AB - Naltriben (NTB) is a selective antagonist for the putative δ2-opioid receptor. We have determined the regional kinetics and pharmacological profile of [3H]naltriben in vivo in mouse brain. After i.v. administration to CD1 mice, [3H]naltriben uptake and retention were high in striatum, cortical regions and olfactory tubercles, and low in superior colliculi and cerebellu. Robust rank order correlation was found between [3H]naltriben uptake in discrete brain regions and prior δ-opioid receptor binding determinations in vitro and in vivo [3H]Naltriben binding in vivo was saturable, and was blocked by the δ-opioid receptor antagonist naltrindole, but not by the μ-opioid receptor antagonist cyprodime or the κ-opioid receptor agonist (trans)-(±)-3,4-dicholoro-N-methyl-N-[2-(1-pyrrolidinyl)- cyclohexyl]benzeneacetamide mesylate (U50, 488H). (E)-7- Benzylidenenaltrexone (BNTX), a selective antagonist for the putative δ1- opioid receptor, was 9.6- to 12.9-fold less potent than naltriben as an inhibitor of [3H]naltriben binding. Thus, the sites labeled by [3H]naltriben in vivo may correspond to the δ2-opioid receptor subtype. Such assignment is not definitive, particularly considering the 4-fold higher brain uptake of naltriben as compared to (E)-7-benzylidenenaltrexone. Moreover, the regional distribution of [3H]naltriben in brains from CXB- 7/BY (CXBK) mice, a strain that shows supraspinal δ1- but not δ2-opioid receptor agonist effects, was quite similar to that found for CD1 mice.

KW - δ-Opioid receptor

KW - Benzylidenenaltrexone

KW - Binding

KW - Brain

KW - CD1 mouse

KW - CXBK mouse

KW - In vivo

KW - Naltriben

UR - http://www.scopus.com/inward/record.url?scp=0032486119&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032486119&partnerID=8YFLogxK

U2 - 10.1016/S0014-2999(98)00268-4

DO - 10.1016/S0014-2999(98)00268-4

M3 - Article

C2 - 9696425

AN - SCOPUS:0032486119

VL - 350

SP - 335

EP - 344

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 2-3

ER -